Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche

The different prostate cancer (PCa) cell populations (bulk and cancer stem cells, CSCs) release exosomes that contain miRNAs that could modify the local or premetastatic niche. The analysis of the differential expression of miRNAs in exosomes allows evaluating the differential biological effect of both populations on the niche, and the identification of potential biomarkers and therapeutic targets. Five PCa primary cell cultures were established to originate bulk and CSCs cultures. From them, exosomes were purified by precipitation for miRNAs extraction to perform a comparative profile of miRNAs by next generation sequencing in an Illumina platform. 1839 miRNAs were identified in the exosomes. Of these 990 were known miRNAs, from which only 19 were significantly differentially expressed: 6 were overexpressed in CSCs and 13 in bulk cells exosomes. miR-100-5p and miR-21-5p were the most abundant miRNAs. Bioinformatics analysis indicated that differentially expressed miRNAs are highly related with PCa carcinogenesis, fibroblast proliferation, differentiation and migration, and angiogenesis. Besides, miRNAs from bulk cells affects osteoblast differentiation. Later, their effect was evaluated in normal prostate fibroblasts (WPMY-1) where transfection with miR-100-5p, miR-21-5p and miR-139-5p increased the expression of metalloproteinases (MMPs) -2, -9 and -13 and RANKL and fibroblast migration. The higher effect was achieved with miR21 transfection. As conclusion, miRNAs have a differential pattern between PCa bulk and CSCs exosomes that act collaboratively in PCa progression and metastasis. The most abundant miRNAs in PCa exosomes are interesting potential biomarkers and therapeutic targets.

[1]  E. Mardis Next-generation DNA sequencing methods. , 2008, Annual review of genomics and human genetics.

[2]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[3]  L. Sáenz,et al.  Secretion of prostatic specific antigen, proliferative activity and androgen response in epithelial-stromal co-cultures from human prostate carcinoma. , 2005, International journal of andrology.

[4]  B. Tysnes,et al.  Tumor-initiating and -propagating cells: cells that we would like to identify and control. , 2010, Neoplasia.

[5]  Sebastian D. Mackowiak,et al.  miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades , 2011, Nucleic acids research.

[6]  M. Mason,et al.  Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts , 2014, Oncotarget.

[7]  Can Liu,et al.  MicroRNA regulation of cancer stem cells. , 2011, Cancer research.

[8]  Tao Li,et al.  miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. , 2012, The Journal of urology.

[9]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[10]  U. Landegren,et al.  Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[11]  Ana Kozomara,et al.  miRBase: annotating high confidence microRNAs using deep sequencing data , 2013, Nucleic Acids Res..

[12]  H. Woo,et al.  Current Status of Biomarkers for Prostate Cancer , 2013, International journal of molecular sciences.

[13]  P. Kantoff,et al.  Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low‐risk, localized prostate cancer , 2013, The Prostate.

[14]  F. Hinman,et al.  EUROPEAN UROLOGY. , 1928, California and western medicine.

[15]  G. Camussi,et al.  Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. , 2011, Cancer research.

[16]  Yang Wang,et al.  Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. , 2014, Gene.

[17]  John Goutsias,et al.  Integrative Identification of Deregulated MiRNA/TF-Mediated Gene Regulatory Loops and Networks in Prostate Cancer , 2014, PloS one.

[18]  J. McKiernan,et al.  Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer , 2012, The Prostate.

[19]  M. Srougi,et al.  miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer , 2012, BMC Urology.

[20]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[21]  L. Chung,et al.  Metastasis initiating cells in primary prostate cancer tissues from transurethral resection of the prostate (TURP) predicts castration‐resistant progression and survival of prostate cancer patients , 2015, The Prostate.

[22]  S. Yano,et al.  Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts , 2011, British Journal of Cancer.

[23]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[24]  B. Burwinkel,et al.  Characterization of extracellular circulating microRNA , 2011, Nucleic acids research.

[25]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[26]  S. Xia,et al.  KLF9, a transcription factor induced in flutamide‐caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells , 2014, The Prostate.

[27]  X. Yao,et al.  Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy , 2011, The Prostate.

[28]  R. Bristow,et al.  Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression , 2014, Oncotarget.

[29]  E. Castellón,et al.  Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer , 2014, International journal of oncology.

[30]  J. Lötvall,et al.  Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes , 2013, Journal of extracellular vesicles.

[31]  T. Sparwasser,et al.  Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer , 2012, Oncoimmunology.

[32]  P. Zhou,et al.  Identification of miR-194-5p as a potential biomarker for postmenopausal osteoporosis , 2015, PeerJ.

[33]  M Bolla,et al.  EAU guidelines on prostate cancer . Part I : screening , diagnosis , and treatment of clinically localised disease , 2012 .

[34]  E. Wentzel,et al.  miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. , 2009, Cancer research.

[35]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[36]  Hongwei Liang,et al.  miR-16 promotes the apoptosis of human cancer cells by targeting FEAT , 2015, BMC Cancer.

[37]  Zhiwei Wang,et al.  Targeting prostate cancer stem cells for cancer therapy. , 2012, Discovery medicine.

[38]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[39]  E. Castellón,et al.  Molecular signature of cancer stem cells isolated from prostate carcinoma and expression of stem markers in different Gleason grades and metastasis. , 2012, Biological research.

[40]  Z. Hall Cancer , 1906, The Hospital.

[41]  M. Srougi,et al.  MicroRNA expression profiles in the progression of prostate cancer--from high-grade prostate intraepithelial neoplasia to metastasis. , 2013, Urologic oncology.

[42]  Clotilde Théry,et al.  Biogenesis and secretion of exosomes. , 2014, Current opinion in cell biology.

[43]  Ran Liu,et al.  Expression Profiling of Exosomal miRNAs Derived from Human Esophageal Cancer Cells by Solexa High-Throughput Sequencing , 2014, International journal of molecular sciences.

[44]  Kiyoshi Asai,et al.  Characterization of endogenous human Argonautes and their miRNA partners in RNA silencing , 2008, Proceedings of the National Academy of Sciences.

[45]  W. Catalona,et al.  Prostate-specific antigen (PSA) should drive doing prostate biopsies. , 2012, Urologic oncology.

[46]  C. Hicks,et al.  Resveratrol and prostate cancer: promising role for microRNAs. , 2011, Molecular nutrition & food research.

[47]  Zhiping Wang,et al.  Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. , 2014, Oncology reports.

[48]  Chi-Ying F. Huang,et al.  miRTarBase: a database curates experimentally validated microRNA–target interactions , 2010, Nucleic Acids Res..

[49]  T. Ochiya,et al.  Interactions between cancer cells and normal cells via miRNAs in extracellular vesicles , 2015, Cellular and Molecular Life Sciences.

[50]  G. Illei,et al.  The Majority of MicroRNAs Detectable in Serum and Saliva Is Concentrated in Exosomes , 2012, PloS one.

[51]  M. Metzker Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.

[52]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[53]  Stefan Holdenrieder,et al.  Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer , 2011, Tumor Biology.

[54]  Krzysztof Fujarewicz,et al.  Analysis options for high-throughput sequencing in miRNA expression profiling , 2014, BMC Research Notes.

[55]  P. Carroll,et al.  Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. , 2011, Cancer research.

[56]  Tao Wang,et al.  Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. , 2015, European urology.

[57]  Björn Olsson,et al.  A miRNA expression signature that separates between normal and malignant prostate tissues , 2011, Cancer Cell International.

[58]  Ya Xiao,et al.  Screening biomarkers of prostate cancer by integrating microRNA and mRNA microarrays. , 2013, Genetic testing and molecular biomarkers.

[59]  F. Hamdy,et al.  Changes in circulating microRNA levels associated with prostate cancer , 2012, British Journal of Cancer.

[60]  E. Kroh,et al.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.

[61]  R. Gomis,et al.  Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. , 2012, The Journal of clinical investigation.

[62]  Douglas D. Taylor,et al.  Exosomal microRNA: a diagnostic marker for lung cancer. , 2008, Clinical lung cancer.

[63]  I. Hofacker RNA Secondary Structure Analysis Using the Vienna RNA Package , 2003, Current protocols in bioinformatics.

[64]  Ihor Batruch,et al.  Collective migration of cancer‐associated fibroblasts is enhanced by overexpression of tight junction‐associated proteins claudin‐11 and occludin , 2014, Molecular oncology.

[65]  B Scaggiante,et al.  Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression , 2011, British Journal of Cancer.

[66]  Jeffrey G. Reid,et al.  Expression profiling of microRNAs by deep sequencing , 2009, Briefings Bioinform..

[67]  Cicek Gercel-Taylor,et al.  MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. , 2008, Gynecologic oncology.

[68]  Charles E. Vejnar,et al.  miRmap: Comprehensive prediction of microRNA target repression strength , 2012, Nucleic acids research.

[69]  A. Llorente,et al.  Exosomal miRNAs as Biomarkers for Prostate Cancer , 2013, Front. Genet..

[70]  P. Altevogt,et al.  Body fluid derived exosomes as a novel template for clinical diagnostics , 2011, Journal of Translational Medicine.

[71]  Miguel Srougi,et al.  Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. , 2011, Urologic oncology.

[72]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[73]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[74]  M. Panaro,et al.  Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: a role for activated fibroblasts and CX3CL1-CX3CR1 axis. , 2009, Cancer research.